Publications by authors named "Donald Lamm"

Claim this Profile
B
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
Roger Li, Patrick J Hensley, Shilpa Gupta, Hikmat Al-Ahmadie, Marko Babjuk, Donald L Lamm

Eur Urol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, Trinity J Bivalacqua, Peter C Black, Donald Lamm

J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, Marianna Zahurak, Gary L Rosner, Donald L Lamm

Eur Urol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer.
Max Kates, Ahmed M Mansour, Donald L Lamm, Neal Shore, Holly Maulhardt

J Urol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
Mathieu Roumiguié, Ashish M Kamat, Trinity J Bivalacqua, Seth P Lerner, Wassim Kassouf, Donald Lamm

Eur Urol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter.
Ashish M Kamat, Niyati Lobo, Seth P Lerner, Roger Li, Justin T Matulay, Donald L Lamm

Bladder Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Ryan L Steinberg, Vignesh T Packiam, Lewis J Thomas, Nathan Brooks, Andrew Vitale, Donald L Lamm

Urol Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment.
Donald L Lamm, Alvaro Morales

Vaccine· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Ryan L Steinberg, Lewis J Thomas, Nathan Brooks, Sarah L Mott, Andrew Vitale, Donald L Lamm

J Urol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG).
Justin T Matulay, Mark Soloway, J Alfred Witjes, Roger Buckley, Raj Persad, Donald L Lamm

BJU Int· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.
Marcus J Daniels, Emily Barry, Mark Schoenberg, Donald L Lamm, Trinity J Bivalacqua

Urol Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
Vignesh T Packiam, Donald L Lamm, Daniel A Barocas, Andrew Trainer, Benjamin Fand

Urol Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Comment.
Donald L Lamm

J Urol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers.
Monika Joshi, Sherri Z Millis, David Arguello, Sheldon L Holder, Donald Lamm

Eur Urol Focus· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm

J Immunother Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm

J Immunother Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.
Ashish M Kamat, Marc Colombel, Debasish Sundi, Donald Lamm, Andreas Boehle

Nat Rev Urol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.
Nicholas M Donin, Karim Chamie, Andrew T Lenis, Allan J Pantuck, Madhu Reddy, Donald L Lamm

Urol Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovation in Bladder Cancer Immunotherapy.
H Barton Grossman, Donald L Lamm, Ashish M Kamat, Stephen Keefe, John A Taylor

J Immunother· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Ashish M Kamat, Richard J Sylvester, Andreas Böhle, Joan Palou, Donald L Lamm

J Clin Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Getting the Most Out of bacillus Calmette-Guérin for Treatment of Bladder Cancer.
Donald L Lamm

J Urol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.050.
Stephen B Williams, Donald L Lamm, Ashish M Kamat

Eur Urol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis